In a nutshell This study examined the use of ibrutinib (Imbruvica) in patients with relapsed or refractory (did not respond to prior treatment) mantle cell lymphoma. The authors concluded that ibrutinib was a safe and effective treatment in these patients. Some background Mantle cell lymphoma is an aggressive form on non-Hodgkin lymphoma....
Read More
In a nutshell This study explored whether treatment with rituximab (Rituxan) improved outcomes and quality of life compared to a watch and wait approach in patients with advanced-stage, follicular lymphoma without symptoms. The authors determined that treatment with rituximab was a safe and effective treatment option. Some background Some patients...
Read More
In a nutshell This study compared the effectiveness of different intensities of chemotherapy in double-hit lymphoma. This study concluded that the chemotherapy combination R-EPOCH was associated with improved time to disease progression. Some background Roughly 8%–10% of patients with diffuse large B-cell lymphoma have a double hit type of...
Read MoreIn a nutshell This study reviewed the use of targeted therapies in diffuse large B-cell lymphoma. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. The standard treatment for DLBCL is the chemoimmunotherapy combination R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and...
Read More
In a nutshell This study compared two chemotherapy regimens, CHOP14 and CHOP21, combined with rituximab (Rituxan) in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that there were no significant differences in survival between the two regimens. Some background Diffuse large B-cell lymphoma (DLBCL) is a commonly...
Read More
In a nutshell This study compared treatments for older patients with mantle cell lymphoma (MCL). This study concluded that treatment with the combination R-CHOP followed by long-term rituximab (Rituxan) treatment was an effective option. Some background The average age at diagnosis for MCL is 65 years. Patients often have extensive disease at...
Read More
In a nutshell This study reported the long-term outcomes of patients with mantle cell lymphoma treated with intense chemoimmunotherapies, without stem cell transplantation (SCT). This study concluded that this treatment combination, without SCT, was safe and effective. Some background Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin...
Read More
In a nutshell This study examined the effectiveness of the combination bortezomib, rituximab, and dexamethasone (BORID) in patients with relapsed or refractory (did not respond to treatment) mantle cell lymphoma. This study concluded that this combination was effective and tolerable in these heavily pretreated patients. Some background Mantle cell...
Read More
In a nutshell This study provided updated guidelines and recommendations for the staging, response assessment, and follow-up of patients with non-Hodgkin lymphoma (NHL). Some background Careful staging of lymphoma is essential, as this provides the basis for treatment decisions. The criteria for NHL staging and the tests used to diagnose, stage,...
Read More
In a nutshell This trial examined intensifying treatment in children with stage 3 or 4 lymphoblastic lymphoma. This study also compared treatments meant to prevent central nervous system involvement. The authors determined that the outcomes were similar regardless of treatment type. Some background Lymphoblastic lymphoma is the second most common...
Read MoreIn a nutshell This study reviewed the use of targeted therapies in pediatric non-Hodgkin lymphoma (pNHL). Some background Due to improvements in treatments, supportive care, and imaging, more than 75% of pNHL patients can be cured. However, there are still many short- and long-term effects of pNHL treatments, such as chemotherapy. Treatments that...
Read More
In a nutshell This study compared the outcomes associated with various treatments for early-stage follicular lymphoma. This study concluded that survival was similar with watchful waiting compared to other early treatments. Some background Follicular lymphoma (FL) is the most common form of slow-growing non-Hodgkin lymphoma. Less than 20% of...
Read More
